文献速递肝病

WNK1通过TPI1促进肝星状细胞糖酵解驱动肝纤维化

With no lysine kinase 1 in hepatic stellate cells promotes mouse and human liver fibrosis through glycolytic triosephosphate isomerase 1.
PubMed 文献 · Hepatology · 2026-08-06

该研究在PDGF-B激活的原代人肝星状细胞中发现WNK1为新激酶,其通过直接磷酸化TPI1并形成相分离凝聚体促进糖酵解和HSC活化;药物或遗传抑制WNK1可减轻小鼠肝纤维化,并在人精切肝片中减少纤维生成。

要点

  • WNK1是PDGF-B激活人HSC中新增的激酶,抑制WNK1可减弱HSC糖酵解。
  • TPI1被鉴定为WNK1直接底物,二者在凝聚体中互作,干扰凝聚体或敲低TPI1/WNK1减少HSC增殖迁移。
  • 药物或遗传抑制WNK1在CCl4及高脂胆碱缺乏L-氨基酸饮食小鼠模型中显著减轻肝纤维化。

核心结论

  • WNK1是此前未识别的通过TPI1介导糖酵解促进HSC活化和肝纤维化的激酶,WNK1-TPI1轴为潜在治疗靶点。

研究设计与样本

  • 基础与转化研究:使用原代人HSC、化学遗传学、质谱、小鼠肝纤维化模型及人精切肝片。

主要发现

  • 磷酸激酶阵列鉴定WNK1为PDGF-B激活的原代人HSC中新激酶。
  • WNK1选择性抑制剂WNK-IN-11减弱PDGF介导的HSC糖酵解(活细胞代谢检测、Glifon-300荧光、Glucose-Glo及GLUT1免疫荧光)。
  • 化学遗传学结合质谱鉴定TPI1为WNK1直接底物,二者在凝聚体中互作。
  • 凝聚体破坏或敲低TPI1或WNK1减少体外HSC增殖和迁移。
  • 药物或遗传抑制WNK1在CCl4及高脂胆碱缺乏L-氨基酸饮食小鼠模型中显著减轻肝纤维化,并在人精切肝片中减少纤维生成。

临床怎么用

  • WNK1-TPI1轴可作为抗肝纤维化药物开发的潜在靶点,但尚未进入临床。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Liver fibrosis and cirrhosis are major global health burdens with limited treatments. Activated HSCs drive fibrosis through increased proliferation, migration, collagen deposition and glycolysis. The aim of this study is to elucidate the signaling events that lead to enhanced glycolysis, subsequent HSC activation, and liver fibrosis. APPROACH AND RESULTS: Utilizing a phospho-kinase array, we identified with no lysine kinase 1 (WNK1) as a new kinase in primary human HSCs activated by the profibrotic PDGF-B. PDGF-mediated glycolysis in HSCs was attenuated by the WNK1 selective inhibitor, WNK-IN-11, as measured by live-cell metabolic assay, Glifon-300 fluorescence, Glucose-Glo assay, and glucose transporter 1 immunofluorescence. To understand how WNK1 promotes glycolysis, we employed chemical genetics where an engineered WNK1 carrying threonine 301 to glycine mutation (WNK1 T301G ) mutant with a modified ATP pocket accommodated a specific ATP-γ-S analogue to thio-phosphorylate its substrates. Thio-phosphorylated proteins were analyzed by mass spectrometry, which identified the glycolytic protein, triosephosphate isomerase 1 (TPI1), as a novel WNK1 direct substrate. TPI1 interacted with WNK1 in condensates, membrane-less phase separation structures. Condensate disruption and knockdown of TPI1 or WNK1 reduced HSC proliferation and migration in vitro. In vivo, pharmacological or genetic WNK1 inhibition significantly attenuated liver fibrosis in carbon tetrachloride and high-fat, choline-deficient, L -amino acid diet mouse models. Finally, WNK1 inhibition reduced fibrogenesis ex vivo in human precision-cut liver slices. CONCLUSIONS: These findings identify WNK1 as a previously unrecognized kinase that promotes HSC activation and liver fibrosis via TPI1-mediated glycolysis, highlighting the WNK1-TPI1 axis as a potential therapeutic target.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Firdaus Z, Khanal S, Washington AM, et al. With no lysine kinase 1 in hepatic stellate cells promotes mouse and human liver fibrosis through glycolytic triosephosphate isomerase 1. Hepatology. 2026. PMID: 42560363. doi:10.1097/HEP.0000000000001833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。